67740-14-1

Upstream product

• 42265-67-8 4-t-butyl-2-chloroaniline 
• 10442-39-4 tetra-n-butylammonium cyanide 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 20330-45-4 4-tert-butylacetanilide 
• 100141-30-8 acetic acid-(4-tert-butyl-2-chloro-anilide) 

Downstream Products

• 1338065-77-2 4-tert-butyl-2-pyrrolidin-1-yl-benzonitrile 
• 1338065-15-8 1-[(4-tert-butyl-2-pyrrolidin-1-yl-phenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea 
• 1338065-78-3 (4-tert-butyl-2-pyrrolidin-1-yl-phenyl)methanamine 
• 1338065-75-0 C₁₁H₁₆ClN 
• 1338065-14-7 1-[(4-tert-butyl-2-chloro-phenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea 

Relevant academic research and scientific papers

Arene Cyanation via Cation-Radical Accelerated-Nucleophilic Aromatic Substitution

Herein we describe a cation radical-accelerated-nucleophilic aromatic substitution (CRA-SNAr) of alkoxy arenes utilizing a highly oxidizing acridinium photoredox catalyst and acetone cyanohydrin, an inexpensive and commercially available cyanide source. This cyanation is selective for carbon-oxygen (C-O) bond functionalization and is applicable to a range of methoxyarenes and dimethoxyarenes. Furthermore, computational studies provide a model for predicting regioselectivity and chemoselectivity in competitive C-H and C-O cyanation of methoxyarene cation radicals.

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active